Nasdaq Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share.
The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 7, 2022, to regain compliance with Nasdaq Rule 5550(a)(2). To regain compliance, the Company's American Depositary Shares representing ordinary shares (“ADSs”) must have a closing bid price of at least US$1.00 per ADS for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by December 7, 2022, the Company may be eligible for additional time to regain compliance or may face delisting.
The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Rules.
As previously reported, on April 22, 2022, the Company received a letter from Nasdaq notifying the Company that it was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. In accordance with Nasdaq Rule 5810(c)(2)(A), within 45 calendar days of receiving this notice, the Company submitted a plan to regain compliance to Nasdaq. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance.
Although Nasdaq notification letters described above have no immediate effect on the Company's listing on Nasdaq, and the Company is working on implementing plans to regain compliance with Nasdaq listing standards, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s minimum stockholders’ equity requirement or minimum bid-price requirement for continued listing.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused
Recent QNRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 08:30:08 PM
- Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO • GlobeNewswire Inc. • 09/09/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:03:37 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/12/2024 08:32:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:01:28 PM
- Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 12:30:00 PM
- Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome • GlobeNewswire Inc. • 08/06/2024 09:00:00 AM
- Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 08:10:00 PM
- Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference • GlobeNewswire Inc. • 06/25/2024 08:05:00 PM
- Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland • GlobeNewswire Inc. • 06/12/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:10:54 PM
- Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2024 08:00:53 PM
- Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 08:10:00 PM
- Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb • IH Market News • 03/13/2024 11:03:39 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/08/2024 09:06:10 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/08/2024 09:04:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:01:51 PM
- Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 03/06/2024 10:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:01:40 PM
- Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM